[Skip to Navigation]
Sign In
December 3, 2020

Error in Author Affiliation

JAMA Oncol. 2021;7(1):140. doi:10.1001/jamaoncol.2020.6961

The Original Investigation titled “Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial,”1 published online October 1, 2020, included an error in the author affiliations. The affiliations for Armando Santoro should have been Humanitas Clinical and Research Center–IRCCS, Humanitas Cancer Center, Rozzano, Milan, Italy, and Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. This article has been corrected.

Yau  T, Kang  Y-K, Kim  T-Y,  et al.  Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial.   JAMA Oncol. 2020. Published online October 1, 2020. doi:10.1001/jamaoncol.2020.4564PubMedGoogle Scholar